Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tivozanib
- Development stage
- Approved
- Lead developer
- AVEO Oncology
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Tivozanib is an oral, small molecule tyrosine kinase inhibitor used to treat advanced renal cell carcinoma (RCC) in adults who have failed at least two prior systemic therapies or whose disease has relapsed. It works by selectively inhibiting the phosphorylation of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3, thereby suppressing angiogenesis and tumor growth. Tivozanib also inhibits other kinases such as c-kit and platelet-derived growth factor receptor beta (PDGFR-β). The drug was developed by Kyowa Kirin and is marketed under the brand name Fotivda by Aveo Oncology. Tivozanib was approved by the FDA in March 2021 for use in relapsed or refractory advanced RCC[3][5][6][8].
- Brand names
- Fotivda
- Other names
- tivozanib hydrochloride monohydrate
02
Targets
EPHB2 (Ephrin type-B receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TEK (Tie2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on tivozanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tivozanib.